Antisense and RNAi Therapeutics Market to Reach USD 19.8 Billion by 2032, Growing at a CAGR of 17.4%

Antisense and RNAi Therapeutics Market: Key Players and Competitive Landscape

Straits Research, a leading provider of business intelligence, research, and analytics, is pleased to announce the release of its latest comprehensive report on the global Antisense and RNAi Therapeutics Market. The report reveals remarkable insights into market trends, growth projections, and key players, positioning the market for significant expansion in the coming years.

Antisense and RNAi Therapeutics Market Insights

According to Straits Research, the global Antisense and RNAi Therapeutics Market size was valued at USD 4.7 billion in 2023 and is projected to grow from USD 5.5 billion in 2024 to a staggering USD 19.8 billion by 2032, with a robust compound annual growth rate (CAGR) of 17.4% during the forecast period (2024–2032).

Request a free request sample  https://straitsresearch.com/report/antisense-and-rnai-therapeutics-market/request-sample

Market Definition and Latest Trends

Antisense and RNAi therapeutics are revolutionary approaches in the field of molecular medicine, offering targeted gene-silencing techniques. These therapeutic strategies involve the use of small RNA molecules to interfere with gene expression, effectively silencing disease-causing genes. The technology has shown tremendous potential in treating a wide range of diseases, including cancer, cardiovascular diseases, respiratory disorders, renal diseases, neurodegenerative disorders, genetic disorders, and infectious diseases.

Latest Trends:

1. Advancements in RNA Interference Technology: Innovations in siRNA (small interfering RNA) and miRNA (microRNA) are driving the market forward, enabling precise targeting of genes.

2. Growing Investment in Research and Development: Increased funding and investment by major pharmaceutical companies are accelerating the development of antisense and RNAi therapeutics.

3. Clinical Success and Regulatory Approvals: Recent clinical trial successes and regulatory approvals are boosting confidence in these therapies, paving the way for their commercialization.

4. Collaborations and Partnerships: Collaborations between biotech companies and academic institutions are fostering innovation and expanding the therapeutic applications of antisense and RNAi technologies.

Key Opportunities

The report identifies several key players contributing to the dynamic growth of the Antisense and RNAi Therapeutics Market:

• GSK plc

• Olix Pharmaceuticals, Inc.

• Sanofi

• Alnylam Pharmaceuticals, Inc.

• Arbutus Biopharma

• Benitec Biopharma Inc.

• Silence Therapeutics

• Ionis Pharmaceuticals, Inc

• Sarepta Therapeutics

• Percheron Therapeutics Limited

This Report is available for purchase on  https://straitsresearch.com/buy-now/antisense-and-rnai-therapeutics-market

Market Segmentations

The Antisense and RNAi Therapeutics Market is segmented based on technology, application, and route of administration:

By Technology:

• RNA Interference

  • siRNA

  • miRNA

• Antisense RNA

By Application:

• Oncology

• Cardiovascular Diseases (CVDs)

• Respiratory Disorders

• Renal Diseases

• Neurodegenerative Disorders

• Genetic Disorders

• Infectious Diseases

• Others

By Route of Administration:

• Intravenous Route

• Subcutaneous Route

• Intrathecal Route

• Pulmonary Delivery

• Intraperitoneal Injection

• Others

About Straits Research

Straits Research is a premier provider of business intelligence, specializing in research, analytics, and advisory services. With a commitment to delivering in-depth insights through comprehensive reports, Straits Research empowers businesses to make informed decisions and stay ahead in today's competitive market landscape.

Contact Us

For more information about the Antisense and RNAi Therapeutics Market report or to purchase the full report, please contact Straits Research:

• Email: sales@straitsresearch.com

• Address: 825 3rd Avenue, New York, NY, USA, 10022

• Phone: +1 646 905 0080 (US), +91 8087085354 (India), +44 203 695 0070 (UK)